Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

crease or remain flat in future periods, due to generic competition and overall demand for the product.

Cost of goods sold increased $0.2 million, or 47%, to $0.5 million for the three months ended March 31, 2009, from $0.3 million for the three months ended March 31, 2008. The increase is substantially due to a change in our product mix, as our authorized generic oxandrolone has become a greater percentage of overall gross sales and carries higher costs of sales than Oxandrin.

Research and development expenses increased by $1.6 million, or 14%, to $12.8 million for the three months ended March 31, 2009, from $11.2 million for the three months ended March 31, 2008. The increase was primarily due to $1.8 million of costs associated with the manufacturing of commercial batches of pegloticase active pharmaceutical ingredient (API) by our third-party manufacturer and an additional severance liability recorded during the quarter. Partially offsetting these higher expenses were lower validation and technology transfer costs relating to our secondary source supplier for pegloticase API.

Selling, general and administrative expenses increased $0.2 million, or 2%, to $9.5 million for the three months ended March 31, 2009, from $9.3 million for the three months ended March 31, 2008. The increase was mainly due to an additional severance liability recorded during the quarter partially offset by lower legal fees as the prior year results reflect expenses for Oxandrin-related patent infringement litigation.

Investment income, net decreased $1.2 million to an expense of $0.2 million for the three months ended March 31, 2009, from income of $1.0 million for the three months ended March 31, 2008. The decrease was primarily attributable to lower dividend and interest income from lower cash, cash equivalent and investment balances and as a result of lower yields earned on these investments.

CO
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
(Date:10/25/2014)... Va. (PRWEB) October 24, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announces its appointment of four ... Workgroup. The workgroup leaders include:, , ... ,     Erik Pupo, Specialist Leader, Deloitte Consulting ...
(Date:10/25/2014)... A new way to produce engineered skin not ... grafting technologies, it also speeds up the healing process, ... the October issue of STEM CELLS Translational Medicine, could ... result from severe burns and chronic wounds. , A ... These wounds heal by contraction, with epithelization (the process ...
(Date:10/25/2014)... Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the ... the Fourth International Symposium on Thymosins in Health and ... "When thymosin beta 4 (TB4) linked with ... peritoneal cavity in a rodent model of stroke, it ... brain parenchyma (the functional tissue of the brain).   The ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... more convenient security to residences and private offices with their state-of-the-art ... businesses, hospitals, schools and the military is now accessible to the ... ... same innovative biometric technology used to enhance Hollywood films like Mission ...
... 27 MichBio, the association for,Michigan,s biosciences industry, ... to its program on day one of its ... Rock Financial ShowPlace Novi, MI. The,event will provide ... bioscience technologies and emerging companies to an audience ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today the company,s,participation and ... investor conferences in September., Conference: NewsMakers ... Millennium Broadway Hotel & Conference Center ... West 44th Street, New York Presentation Date: Thursday, September ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 3
(Date:10/29/2014)... EAST LANSING, Mich. – As bodies decompose, their ... Deciphering the clues they provide could mean the ... murder. , Michigan State University is using a ... to help Detroit death-scene investigators examine these changing ... such as geographical location of death, gender, race, ...
(Date:10/29/2014)... Virtually all organisms in the living world compete ... differ strongly in how much they invest into ... and eager to get access to high-quality resources, ... prudent use of the lower-quality resources that are ... competitiveness in animal and human societies seems to ...
(Date:10/28/2014)... news release is available in German . ... close relatives, the chimpanzees, acquire sufficient food when times ... National Park in Côte d,Ivoire researchers of the Max ... a clear example of how great apes can acquire ... show that chimpanzees make their sleeping nests more en ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Evolution of competitiveness 2Evolution of competitiveness 3The early chimp gets the fig 2The early chimp gets the fig 3
... 2007Professor Gilles Gauthier of Universit Lavals Centre dtudes nordiques ... up the ArticWOLVES project as part of International Polar ... the research project aims to better understand the impact ... polar ecosystems. Dating back to the 1960s, Centre ...
... 24, 2007) New research published in the October ... Surgeons suggests that pregnant women suspected of having appendicitis ... the appendix) that can result in early delivery or ... the need to require more accurate diagnosis to avoid ...
... The vast majority of patients who had ... did not need mitral valve surgery three years ... improved function of the left ventricle (commonly known ... week at the Cardiovascular Research Foundations (CRF) nineteenth ...
Cached Biology News:$2.8 million for research into the impact of climate change on tundra wildlife 2Pregnant women at risk for unnecessary operations due to misdiagnosis of appendicitis 2New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3
...
... formation of phosphodiester bonds in the presence ... hydroxyl and 5' phosphate termini. The unique ... can be performed in 5 minutes (1). ... this enzyme. A T4 DNA Ligase ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
Biology Products: